ACHL
Achilles Therapeutics PLC ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$63.22M
P/E Ratio
—
EPS
$-1.66
Beta
1.25
52W High
$0.00
52W Low
$0.00
50-Day MA
$1.32
200-Day MA
$1.03
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Achilles Therapeutics PLC ADR
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-67.23M |
| Operating Margin | 0.00% |
| Return on Equity | -52.10% |
| Return on Assets | -30.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.51 |
| Price-to-Book | 0.61 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $41.10M |
| Float | $20.85M |
| % Insiders | 6.29% |
| % Institutions | 83.10% |
Data last updated: 4/7/2026